دورية أكاديمية
Advancing translational research for colorectal immuno-oncology.
| العنوان: | Advancing translational research for colorectal immuno-oncology. |
|---|---|
| المؤلفون: | Thomas EM; Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia., Wright JA; Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia., Blake SJ; Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia., Page AJ; School of Biomedicine, The University of Adelaide, Adelaide, SA, Australia.; Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia., Worthley DL; Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia., Woods SL; Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia. susan.woods@adelaide.edu.au.; Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia. susan.woods@adelaide.edu.au. |
| المصدر: | British journal of cancer [Br J Cancer] 2023 Oct; Vol. 129 (9), pp. 1442-1450. Date of Electronic Publication: 2023 Aug 10. |
| نوع المنشور: | Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK Original Publication: London, Lewis. |
| مواضيع طبية MeSH: | Brain Neoplasms* , Colorectal Neoplasms*, Animals ; Mice ; Humans ; Translational Research, Biomedical ; Medical Oncology ; Microsatellite Instability ; DNA Mismatch Repair |
| مستخلص: | Colorectal cancer (CRC) is a common and deadly disease. Unfortunately, immune checkpoint inhibitors (ICIs) fail to elicit effective anti-tumour responses in the vast majority of CRC patients. Patients that are most likely to respond are those with DNA mismatch repair deficient (dMMR) and microsatellite instability (MSI) disease. However, reliable predictors of ICI response are lacking, even within the dMMR/MSI subtype. This, together with identification of novel mechanisms to increase response rates and prevent resistance, are ongoing and vitally important unmet needs. To address the current challenges with translation of early research findings into effective therapeutic strategies, this review summarises the present state of preclinical testing used to inform the development of immuno-regulatory treatment strategies for CRC. The shortfalls and advantages of commonly utilised mouse models of CRC, including chemically induced, transplant and transgenic approaches are highlighted. Appropriate use of existing models, incorporation of patient-derived data and development of cutting-edge models that recapitulate important features of human disease will be key to accelerating clinically relevant research in this area. (© 2023. The Author(s).) |
| References: | Sci Rep. 2018 May 1;8(1):6854. (PMID: 29717179) Nat Med. 2011 Oct 23;17(11):1514-20. (PMID: 22019887) Clin Cancer Res. 2015 Apr 1;21(7):1639-51. (PMID: 25589619) J Clin Oncol. 2022 May 10;40(14):1562-1573. (PMID: 35258987) Cancer Metastasis Rev. 1998-1999;17(3):279-84. (PMID: 10352881) J Immunother Cancer. 2021 Jan;9(1):. (PMID: 33495297) Lancet Oncol. 2022 Jul;23(7):876-887. (PMID: 35636444) J Immunother Cancer. 2019 Jul 23;7(1):193. (PMID: 31337439) Nat Biotechnol. 2017 Jun;35(6):569-576. (PMID: 28459449) Cell Rep. 2019 Aug 13;28(7):1729-1743.e5. (PMID: 31412243) Cell Death Dis. 2021 Nov 27;12(12):1109. (PMID: 34839348) Cell Death Differ. 2018 Mar;25(3):616-633. (PMID: 29305587) Cancer Discov. 2011 Nov;1(6):508-23. (PMID: 22586653) Clin Transl Med. 2021 Jan;11(1):e253. (PMID: 33463049) BMC Genomics. 2014 Mar 13;15:190. (PMID: 24621249) Gastroenterology. 1998 May;114(5):873-7. (PMID: 9558273) Lancet. 2019 Oct 19;394(10207):1467-1480. (PMID: 31631858) N Engl J Med. 2020 Dec 3;383(23):2207-2218. (PMID: 33264544) Cancer Lett. 2020 Feb 1;470:84-94. (PMID: 31610266) Cancer Cell. 2018 Jun 11;33(6):954-964. (PMID: 29657127) N Engl J Med. 2015 Jun 25;372(26):2509-20. (PMID: 26028255) Nature. 2017 Dec 7;552(7683):116-120. (PMID: 29186113) Proc Natl Acad Sci U S A. 2021 Nov 9;118(45):. (PMID: 34725151) Immunology. 2019 Sep;158(1):35-46. (PMID: 31429085) Immunity. 2016 Mar 15;44(3):609-621. (PMID: 26944201) Nat Commun. 2018 Jan 2;9(1):32. (PMID: 29296022) Nat Rev Cancer. 2017 Dec;17(12):751-765. (PMID: 29077691) Cell. 1995 Jul 28;82(2):321-30. (PMID: 7628020) Oncoimmunology. 2018 Mar 15;7(6):e1433981. (PMID: 29872568) J Carcinog. 2011 Mar 24;10:9. (PMID: 21483655) Nat Rev Gastroenterol Hepatol. 2022 Feb;19(2):93-94. (PMID: 34907331) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) Int J Cancer. 2006 Jan 1;118(1):25-34. (PMID: 16049979) World J Gastroenterol. 2008 Jul 7;14(25):3937-47. (PMID: 18609676) Nat Cancer. 2021 Oct;2(10):1071-1085. (PMID: 34738089) Am J Pathol. 2001 Jul;159(1):297-304. (PMID: 11438476) Gastroenterology. 2021 Mar;160(4):1284-1300.e16. (PMID: 33217448) Gastroenterology. 2010 Mar;138(3):993-1002.e1. (PMID: 19931261) Cancer Res. 2015 Sep 15;75(18):3800-11. (PMID: 26208901) Nat Cancer. 2021 Nov;2(11):1124-1135. (PMID: 35122060) Immunity. 2020 Jan 14;52(1):17-35. (PMID: 31940268) Science. 2021 Mar 26;371(6536):. (PMID: 33766858) Cancer. 1975 Dec;36(6 Suppl):2441-4. (PMID: 1212662) Nature. 2018 Feb 22;554(7693):538-543. (PMID: 29443964) Int J Mol Sci. 2021 Sep 28;22(19):. (PMID: 34638774) Gastroenterology. 2021 Oct;161(4):1288-1302.e13. (PMID: 34224739) Exp Mol Med. 2018 Aug 7;50(8):1-9. (PMID: 30089794) Cell. 1990 Jun 1;61(5):759-67. (PMID: 2188735) J Clin Oncol. 2020 Jan 1;38(1):11-19. (PMID: 31725351) Cancer Discov. 2015 Jan;5(1):43-51. (PMID: 25358689) Cancer Immunol Immunother. 2014 Aug;63(8):807-19. (PMID: 24777614) Carcinogenesis. 2009 Feb;30(2):183-96. (PMID: 19037092) Int J Mol Sci. 2021 Feb 10;22(4):. (PMID: 33578709) J Immunother Cancer. 2019 Feb 8;7(1):37. (PMID: 30736857) Cell. 2015 Sep 24;163(1):39-53. (PMID: 26406370) Nat Rev Cancer. 2016 Dec;16(12):759-773. (PMID: 27687979) Lancet Oncol. 2021 May;22(5):665-677. (PMID: 33812497) PLoS One. 2011;6(7):e22114. (PMID: 21799775) Nat Med. 2020 Apr;26(4):566-576. (PMID: 32251400) J Immunother Cancer. 2021 Mar;9(3):. (PMID: 33782107) Science. 2017 Oct 13;358(6360):234-238. (PMID: 28912133) Science. 1990 Jan 19;247(4940):322-4. (PMID: 2296722) Mol Ther. 2020 Dec 2;28(12):2553-2563. (PMID: 32827461) Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):361-375. (PMID: 30886395) Cancer Immunol Immunother. 2020 Jul;69(7):1279-1292. (PMID: 32185408) Trends Mol Med. 2001 Aug;7(8):369-73. (PMID: 11516998) Sci Rep. 2019 Dec 27;9(1):20128. (PMID: 31882868) Immunity. 2021 Dec 14;54(12):2812-2824.e4. (PMID: 34861182) Int J Mol Sci. 2019 Aug 25;20(17):. (PMID: 31450712) Inflamm Bowel Dis. 2010 Apr;16(4):559-67. (PMID: 19785028) Gastroenterology. 2021 Mar;160(4):1224-1239.e30. (PMID: 33197448) BMC Genomics. 2020 Jan 2;21(1):2. (PMID: 31898484) Cancer Lett. 2014 Jun 1;347(2):191-5. (PMID: 24632531) Science. 2018 Jan 5;359(6371):97-103. (PMID: 29097493) Nat Rev Cancer. 2018 Jul;18(7):407-418. (PMID: 29692415) Gastroenterology. 2020 Jan;158(2):322-340. (PMID: 31586566) Lab Anim Res. 2020 Nov 19;36(1):43. (PMID: 33292783) CA Cancer J Clin. 2018 May;68(3):217-231. (PMID: 29485237) Cell. 2019 Nov 14;179(5):1177-1190.e13. (PMID: 31730856) Cancer Prev Res (Phila). 2011 May;4(5):684-93. (PMID: 21436383) Nat Med. 2021 Jan;27(1):152-164. (PMID: 33398162) Cell. 2020 Apr 16;181(2):442-459.e29. (PMID: 32302573) Cancer Cell Int. 2021 Oct 20;21(1):552. (PMID: 34670584) Front Immunol. 2020 Nov 30;11:615056. (PMID: 33329610) Cancer Immunol Res. 2016 Oct;4(10):845-857. (PMID: 27589875) mBio. 2013 Nov 05;4(6):e00692-13. (PMID: 24194538) J Clin Invest. 2022 Apr 15;132(8):. (PMID: 35230972) Trends Immunol. 2020 Aug;41(8):652-664. (PMID: 32654925) Gastroenterology. 2014 Nov;147(5):1064-72.e5. (PMID: 25088490) Cancer Res. 1975 Sep;35(9):2434-9. (PMID: 1149045) PLoS One. 2014 Apr 24;9(4):e96023. (PMID: 24763434) Nat Microbiol. 2019 Dec;4(12):2319-2330. (PMID: 31501538) Nature. 2020 Sep;585(7826):509-517. (PMID: 32968260) Cell Host Microbe. 2013 Aug 14;14(2):207-15. (PMID: 23954159) Science. 2018 Jan 5;359(6371):91-97. (PMID: 29097494) Nature. 2016 Apr 28;532(7600):512-6. (PMID: 27096360) J Clin Oncol. 2022 Jan 10;40(2):161-170. (PMID: 34637336) Gut. 2019 Apr;68(4):684-692. (PMID: 29666172) Cell Stem Cell. 2016 Jun 2;18(6):827-838. (PMID: 27212702) Gastroenterology. 2010 Mar;138(3):820-2. (PMID: 20102757) Sci Immunol. 2020 Oct 2;5(52):. (PMID: 33008914) Nat Biotechnol. 2017 Jun;35(6):577-582. (PMID: 28459450) Cancer Discov. 2018 Nov;8(11):1358-1365. (PMID: 30309862) Gene. 2018 Nov 30;677:299-307. (PMID: 30121380) Biostatistics. 2019 Apr 1;20(2):273-286. (PMID: 29394327) Front Cell Infect Microbiol. 2021 Sep 21;11:711055. (PMID: 34621688) Cancer Biol Ther. 2009 Jul;8(14):1313-7. (PMID: 19502780) N Engl J Med. 2022 Jun 23;386(25):2363-2376. (PMID: 35660797) Science. 2017 Jul 28;357(6349):409-413. (PMID: 28596308) Oncoimmunology. 2020 Aug 31;9(1):1809947. (PMID: 32939327) Int J Mol Med. 1998 Aug;2(2):221-224. (PMID: 9855692) FASEB J. 2018 Mar;32(3):1537-1549. (PMID: 29146734) Lancet Oncol. 2019 Jun;20(6):849-861. (PMID: 31003911) J Immunother. 2019 Feb/Mar;42(2):33-42. (PMID: 30586347) Gut. 2018 Nov;67(11):1984-1994. (PMID: 29437871) |
| معلومات مُعتمدة: | R01 CA241728 United States CA NCI NIH HHS |
| SCR Disease Name: | Turcot syndrome |
| تواريخ الأحداث: | Date Created: 20230810 Date Completed: 20231108 Latest Revision: 20240210 |
| رمز التحديث: | 20240210 |
| مُعرف محوري في PubMed: | PMC10628092 |
| DOI: | 10.1038/s41416-023-02392-x |
| PMID: | 37563222 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder كن أول من يترك تعليقا!